Altogether, this indicates that substantial changes on a tau-PET scan occur in rather advanced clinical and biological stages of AD, which may explain why tau-PET in the current mix of Aβ-positive and Aβ-negative CU individuals did not outperform plasma p-tau217 in predicting future cognitive decline. The gene discussed is MAPT; the disease is Mental deterioration.